Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,124Revenue (TTM) $M783Net Margin (%)-71.5Altman Z-Score0.1
Enterprise Value $M1,750EPS (TTM) $-7.8Operating Margin %-74.6Piotroski F-Score2
P/E(ttm)--Beneish M-Score-5.6Pre-tax Margin (%)-80.0Higher ROA y-yN
Price/Book2.110-y EBITDA Growth Rate %--Quick Ratio1.2Cash flow > EarningsY
Price/Sales1.45-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %-405.0ROA % (ttm)-29.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-66.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M73.7ROIC % (ttm)-41.9Gross Margin Increase y-yN

Gurus Latest Trades with IPXL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

IPXL is held by these investors:



IPXL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
NESTOR MICHAELPresident, Impax Specialty 2017-05-17Sell857$16.48-7.46view
NESTOR MICHAELPresident, Impax Specialty 2017-05-12Sell700$17.11-10.87view
BENET LESLIE ZDirector 2016-08-15Sell10,092$22.81-33.14view
SCHLOSSBERG MARK ASVP and General Counsel 2015-09-11Sell7,457$43.3-64.78view
NESTOR MICHAELPresident, Impax Pharm. 2015-09-10Sell5,000$43.56-64.99view
FLEMING NIGELDirector 2015-08-31Sell29,166$41.02-62.82view
MARKBREITER MICHAELDirector 2015-08-31Sell28,000$41.7-63.43view
BENET LESLIE ZDirector 2015-08-31Sell20,000$40.92-62.73view
SCHLOSSBERG MARK ASVP and General Counsel 2015-08-27Sell4,649$43.41-64.87view
TERRERI PETER RDirector 2015-08-27Sell4,833$43.93-65.29view

Quarterly/Annual Reports about IPXL:

News about IPXL:

Articles On GuruFocus.com
Impax to Present at the Bank of America Merrill Lynch Healthcare Conference May 11 2017 
Impax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin Tab Apr 26 2017 
Impax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig® (Zolmi Apr 21 2017 
Impax to Report First Quarter 2017 Results on May 10, 2017 Apr 06 2017 
Impax Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray Mar 31 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 

More From Other Websites
Impax to Present at the UBS Global Healthcare Conference May 17 2017
Edited Transcript of IPXL earnings conference call or presentation 10-May-17 12:30pm GMT May 16 2017
ETFs with exposure to Impax Laboratories, Inc. : May 15, 2017 May 15 2017
These Stocks Show Change of Direction May 15 2017
Impax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan May 11 2017
Impax to Present at the Bank of America Merrill Lynch Healthcare Conference May 11 2017
Investor Network: Impax Laboratories, Inc. to Host Earnings Call May 10 2017
Impax Labs reports 1Q loss May 10 2017
Impax Reports First Quarter 2017 Financial Results May 10 2017
Merck cholesterol drug Vytorin faces competition from Impax, Teva generics Apr 26 2017
FDA approves Impax generic of Merck's cholesterol drug Vytorin Apr 26 2017
Impax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin... Apr 26 2017
Vetr Crowd Urges Sell For Impax Laboratories Apr 24 2017
Impax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig®... Apr 21 2017
Blog Coverage AbbVie's HCV Regimen Achieves 99% Cure Rate in Phase III Study Apr 21 2017
Impac Secured Assets Corp. Mortgage Pass-Through Certificates, Series 2006-5 -- Moody's downgrades... Apr 13 2017
Impax to Report First Quarter 2017 Results on May 10, 2017 Apr 06 2017
Impax (IPXL) Up 35.3% Since Earnings Report: Can It Continue? Apr 04 2017
Impax Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray Mar 30 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)